

Abstract Plain Language Summaries at Scientific Congresses



What are abstract plain language summaries (APLS)?

APLS use simple visuals, plain language and consistent terminology to describe the research presented at scientific congresses, or meetings. Each APLS represents a small piece of the complete body of data available on the drug and disease area today.

APLS reports represent results of only one study. Researchers must look at the results of many types of studies to understand whether a study drug works, how it works, and whether it is safe to prescribe. The results *might be different from the outcome of other* studies that researchers have presented in the past. It's important to note that these data are investigational, and the treatments may not be approved in these settings by regulatory agencies.

WHO ARE APLS FOR?

APLS can help research findings be accessible and understandable to anyone seeking this information. Audiences may include but are not limited to patients, caregivers, and healthcare professionals.

WHAT INFORMATION DO **APLS INCLUDE?**

APLS summarize the original

HOW ARE APLS USED?

APLS can help people better understand the research data in presentations at scientific congresses.

WHY DOES PFIZER **DEVELOP APLS?**

Research findings often use terms that can be too complex for many non-scientists to understand. APLS provide recent research results in a clear way for non-scientists.

Presentations will go live on the dates marked below.

content of a scientific abstract. They describe the main aims and findings of a research study in an easy-to-understand format by following health literacy best practices.



American Association for Cancer Research (AACR) Annual Meeting Orlando, FL & Online | April 14-19, 2023

PFIZER ABSTRACT PLAIN LANGUAGE SUMMARIES AND ACCOMPANYING SCIENTIFIC PRESENTATIONS **AT AACR 2023**

Prostate Cancer

Treatment patterns and overall survival among men with metastatic castration-resistant prostate cancer harboring DDR mutations

Live Sunday, April 16

Melanoma

Randomized phase 3 study (STARBOARD) evaluating encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for firstline treatment of unresectable

locally advanced or metastatic **BRAF V600-mutant melanoma**

Live Monday, April 17

VIEW PLAIN LANGUAGE SUMMARY ightarrow

VIEW PRESENTATION \rightarrow

VIEW PLAIN LANGUAGE SUMMARY ightarrow

VIEW PRESENTATION \rightarrow



